Dhir Gala, Fady Botros, and Amgad N. Makaryus authored the article entitled "The Beneficial Effects of Glucagon-Like Peptide-1 Agonists on Blood Pressure: A Comprehensive Review," which was published in Volume 26, Issue 12 of Reviews in Cardiovascular Medicine (RCM). (https://www.imrpress.com/journal/RCM/26/12/10.31083/RCM45204)

 

Dr. Amgad N. Makaryus
Departments of Medicine and Cardiology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY 11549, USA
Department of Cardiology, Cardiovascular Institute at Northwell Health, Long Island, NY 11040, USA

 

We are honored to invite Dr. Amgad N. Makaryus to interpret the article. Dr. Makaryus grew up in New York and completed medical school training at the State University of New York, Downstate Medical Center in 2000. Dr. Makaryus is board-certified in internal medicine and cardiology. He also received certification from the National Board of Echocardiography, Certification Board of Nuclear Cardiology, Society of Cardiovascular Computed Tomography, and level II training in cardiac MRI. He is a founding member of the Society of Cardiovascular CT, a fellow of the American College of Cardiology, a member of the American Heart Association, the American Society of Echocardiography, the North American Society of Cardiovascular Imaging, and the American College of Physicians.

Dr. Makaryus has authored over 250 peer-reviewed publications and book chapters. His research interests include the ideal application and integration of cardiovascular imaging into the appropriate diagnosis and management of patients with and at risk for cardiovascular disease.

 

Author's Interpretation

This video presents a comprehensive overview of the cardiovascular effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), with a particular focus on their impact on blood pressure.

While originally developed for glycemic control, GLP-1 RAs demonstrate broader cardiometabolic benefits, including modest reductions in blood pressure, weight loss, improved endothelial function, and anti-inflammatory effects. Multiple mechanisms contribute to blood pressure lowering, such as vascular modulation, autonomic regulation, renal effects, and weight reduction.

Evidence from major clinical trials (e.g., LEADER, REWIND, SUSTAIN-6, and SURMOUNT-1) supports their role in reducing cardiovascular events alongside modest decreases in systolic blood pressure. Although their antihypertensive effect is less pronounced than that of traditional agents, GLP-1 RAs provide additive benefits when used in combination with standard therapies.

Overall, GLP-1 RAs represent a valuable adjunctive strategy for comprehensive cardiovascular risk reduction, particularly in patients with coexisting hypertension, diabetes, and obesity, though further research is needed to refine long-term applications and patient selection.

 

Original Article

The Beneficial Effects of Glucagon-Like Peptide-1 Agonists on Blood Pressure: A Comprehensive Review: https://www.imrpress.com/journal/RCM/26/12/10.31083/RCM45204

 

Related Articles:

Beyond Diabetes: A Review of Emerging Indications for Glucagon-Like Peptide-1 Receptor Agonists: https://www.imrpress.com/journal/RCM/27/1/10.31083/RCM44528

Resistant Hypertension: Integration of Novel Agents and Interventional Approaches in Clinical Practice: https://www.imrpress.com/journal/RCM/27/1/10.31083/RCM45429

Association Between Glucagon-Like Peptide-1 Receptor Agonists and Major Adverse Cardiovascular Outcomes Based on Race and Sex Among Patients With and Without Diabetes Mellitus: A Meta-Analysis of Nine Randomized Controlled Trials: https://www.imrpress.com/journal/RCM/27/1/10.31083/RCM45797